FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Brzeczko Albert W (Last) (First) (Middle) C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 (Street) PALATINE IL 60067 (City) (State) (Zip)						2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC [ACUR] 3. Date of Earliest Transaction (Month/Day/Year) 01/04/2021 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)				2. Trans Date (Month/	saction	ear)	2A. Deemo Execution if any (Month/Da	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,		red (A)	or	5. Amour Securitie Beneficia Owned F	nt of s ally following	Form (D) o	n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	Amount (A) or		ice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 01/					4/202	/2021			M ⁽¹⁾		43,33	43,334 A		(2)	368,	368,668(3)		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date (Month/Day/Year) if any (Month/Day/Year)		ate, Transact			5. Numborf Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	6. Date E Expiration (Month/E	n Date	of Securities		ties 1g e Secu		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amo or Num of Shar	ber					
Restricted Stock Unit (2017 Plan)	\$0.01 ⁽²⁾	01/04/2021			М		9,334		(5)		(5)	Common Stock	9,3	34	(4)	111,33	32	D	
Restricted Stock Unit (2017 Plan)	\$0.01 ⁽²⁾	01/04/2021			М		34,000		(6)		(6)	Common Stock	34,0	000	(4)	77,33	2	D	

Explanation of Responses:

- 1. Represents exchange of restricted stock units.
- 2. Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.
- 3. Does not include Restricted Stock Units.
- 4. Not Applicable.
- 5. 28,000 Restricted Stock Units were granted on December 11, 2017 and were 100% vested on December 11, 2018. Distributions in respect of this vested Restricted Stock Units will be made in three equal installments on the first business day of each of January 2020, 2021, and 2022 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.
- 6. 102,000 Restricted Stock Units were granted on December 11, 2018 and were 100% vested on December 11, 2019. Distributions in respect of this vested Restricted Stock Units will be made in three equal installments on the first business day of each of January 2021, 2022, and 2023 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

01/06/2021

** Signature of Reporting Person

/s/ Albert W. Brzeczko

Date

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.